近日，美国制药巨头礼来公司与人工智能领域的领先机构OpenAI宣布达成合作。此次合作旨在利用OpenAI的生成式AI技术，共同开发新型抗菌药物，以应对日益增长的耐药性病原体威胁。
据悉，这一合作结合了礼来公司的药物研发专长与OpenAI的先进人工智能技术。当地时间25日，双方正式宣布了这一重要合作。在合作新闻发布会上，OpenAI首席运营官Brad Lightcap表示，AI技术的持续进步为制药行业带来了前所未有的创新突破机会。他相信，生成式AI技术能够大幅度提高新药研发的效率与成功率。
礼来公司的首席信息与数字官Diogo Lau同样对这次合作寄予厚望。他表示，生成式AI技术在加速发现新型抗菌剂的同时，还为开发定制化、专门技术以对抗耐药性病原体开辟了新的机遇。这一合作将助力礼来公司更好地应对全球公共卫生挑战，为人类的健康事业作出更大贡献。
此次合作的达成标志着人工智能技术在制药领域的进一步深入。期待双方能够借助各自的优势，共同推动新药研发进程，为抗击耐药性病原体提供新的解决方案。
英语如下：
News Title: “OpenAI Teams Up with Lilly to Revolutionize Antibiotic Drug Development with AI Technology”
Keywords: OpenAI collaborates with pharmaceutical giant, generative AI in drug development, AI enabling the pharmaceutical industry
News Content:
Title: OpenAI Teams Up with Lilly Pharmaceutical Giant to Jointly Develop New Antimicrobial Drugs Using Generative AI Technology
Recently, American pharmaceutical giant Lilly has announced a collaboration with OpenAI, a leading organization in the field of artificial intelligence. This collaboration aims to utilize OpenAI’s generative AI technology to develop new antimicrobial drugs in response to the increasing threat of drug-resistant pathogens.
It is understood that this collaboration combines the expertise of drug development from Lilly with the advanced AI technology of OpenAI. On the 25th, both sides officially announced this significant collaboration. At the joint news conference, Brad Lightcap, Chief Operating Officer of OpenAI, expressed that the continuous progress of AI technology has brought unprecedented opportunities for innovative breakthroughs in the pharmaceutical industry. He believes that generative AI technology can significantly improve the efficiency and success rate of new drug development.
Diogo Lau, Chief Information and Digital Officer of Lilly, also holds high hopes for this collaboration. He stated that generative AI technology not only accelerates the discovery of new antibacterial agents but also opens up new opportunities for developing customized and specialized technologies to combat drug-resistant pathogens. This collaboration will help Lilly better address global public health challenges and make greater contributions to human health.
The achievement of this collaboration marks the further deepening of AI technology in the pharmaceutical field. It is expected that both sides will leverage their respective strengths to jointly promote the process of new drug development and provide new solutions for fighting drug-resistant pathogens.
【来源】https://www.ithome.com/0/777/692.htm
Views: 3